Management of Mevalonate Kinase Deficiency: A Pediatric Perspective
Open Access
- 5 June 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 1150
- https://doi.org/10.3389/fimmu.2020.01150
Abstract
Background: Mevalonate kinase deficiency (MKD) is an inborn error of metabolism leading to a syndrome characterized by recurrent inflammation. This clinically manifests itself as fever and can be accompanied by gastrointestinal symptoms, oral ulcers, cervical lymphadenopathy, and skin rash. Methods: We searched Pubmed, Embase, Cochrane, and CINAHL for relevant articles. All articles were screened by both authors. Relevant articles were included in this review. Results: The interleukin-1 antagonist canakinumab is the only well-studied and effective treatment for MKD patients with 35% of patients reaching complete remission in a large randomized controlled trial. Other therapeutic options include glucocorticoids and the IL-1 antagonist anakinra, although the level of evidence for these treatments is weaker. If patients fail to these treatments, the biologicals etanercept or tocilizumab can be used. Mildly affected patients might benefit from cheaper, less invasive treatments such as paracetamol and NSAIDs. Conclusion: Canakinumab is the only evidence-based treatment for mevalonate kinase deficiency. However, the costs limit availability for many patients. Cheaper and more readily available options include glucocorticoids, anakinra, etanercept, and tocilizumab, although there is limited evidence supporting these treatments.This publication has 21 references indexed in Scilit:
- 25-Hydroxycholesterol suppresses interleukin-1–driven inflammation downstream of type I interferonScience, 2014
- Interleukin 6 Blockade for Hyperimmunoglobulin D and Periodic Fever SyndromeJCR: Journal of Clinical Rheumatology, 2014
- On-demand anakinra treatment is effective in mevalonate kinase deficiencyAnnals Of The Rheumatic Diseases, 2011
- Long-Term Follow-Up, Clinical Features, and Quality of Life in a Series of 103 Patients With Hyperimmunoglobulinemia D SyndromeMedicine, 2008
- Mevalonic Aciduria Cured by Bone Marrow TransplantationThe New England Journal of Medicine, 2007
- Allogeneic Bone Marrow Transplantation in Mevalonic AciduriaThe New England Journal of Medicine, 2007
- A role for geranylgeranylation in interleukin‐1β secretionArthritis & Rheumatism, 2006
- EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committeesAnnals Of The Rheumatic Diseases, 2004
- Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndromeClinical Pharmacology & Therapeutics, 2004
- Hyperimmunoglobulinemia D and Periodic Fever SyndromeMedicine, 1994